Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International Journal of Neuroscience

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/00207454.2016.1232256PMID 27586690
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Atrial fibrillation and risk of stroke: a nationwide cohort study.

  2016cited by this paper
• Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry.

  2016cited by this paper
• Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke.

  2016cited by this paper
• Response by Orito and Morioka to Letter Regarding Article, "Leakage Sign for Primary Intracerebral Hemorrhage: A Novel Predictor of Hematoma Growth".

  2016cited by this paper
• Target-specific Oral Anticoagulants in the Emergency Department.

  2016cited by this paper
• Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.

  2016cited by this paper
• Abstract 212: Andexanet Alfa, a Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers

  2016cited by this paper
• Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage

  2016cited by this paper
• Mechanical Thrombectomy Improves Functional Outcomes Independent of Pretreatment With Intravenous Thrombolysis

  2016cited by this paper
• Therapeutic Advances in Neurological Disorders

  2016cited by this paper
• Control de la anticoagulacion en pacientes con fibrilacion auricular no valvular asistidos en atencion primaria en Espana. Estudio PAULA

  2015cited by this paper
• Edoxaban: A Review in Nonvalvular Atrial Fibrillation

  2015cited by this paper
• Stroke: Highlights of Selected Articles

  2015cited by this paper
• Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Guidelines, Update 2014

  2015cited by this paper
• Is Edoxaban Cost-Effective For Non-Valvular Atrial Fibrillation Patients Treated With Vitamin K Antagonists In Spain?

  2015cited by this paper
• Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation

  2015cited by this paper
• The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults

  2015cited by this paper
• Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany

  2015cited by this paper
• Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study.

  2015cited by this paper
• Rates and Determinants of 5-Year Outcomes After Atrial Fibrillation–Related Stroke: A Population Study

  2015cited by this paper
• Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.

  2015cited by this paper
• Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.

  2015cited by this paper
• Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa

  2015cited by this paper
• Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?

  2015cited by this paper
• Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule

  2015cited by this paper
• Novel antidotes for target specific oral anticoagulants

  2015cited by this paper
• Effective Reversal of Edoxaban-associated Bleeding with Four-factor Prothrombin Complex Concentrate in a Rabbit Model of Acute Hemorrhage

  2015cited by this paper
• Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry

  2015cited by this paper
• Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.

  2015cited by this paper
• Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis

  2015cited by this paper
• Quality of Vitamin K Antagonist Anticoagulation in Spain: Prevalence of Poor Control and Associated Factors.

  2015cited by this paper
• Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

  2015cited by this paper
• Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate

  2015cited by this paper
• Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view

  2015cited by this paper
• Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review

  2015cited by this paper
• Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database.

  2015cited by this paper
• Adherence to Guidelines for Antithrombotic Therapy in Patients with Atrial Fibrillation According to CHADS2 Score before and after Stroke: A Multicenter Observational Study from Korea

  2015cited by this paper
• Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.

  2015cited by this paper
• Adherence to oral anticoagulation in secondary stroke prevention--the first year of direct oral anticoagulants.

  2015cited by this paper
• Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.

  2015cited by this paper
• Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study

  2015cited by this paper
• Abstract 11748: Edoxaban versus Warfarin in Patients at Increased Risk of Falling - A Subgroup Analysis of the ENGAGE AF-TIMI 48 Trial

  2015cited by this paper
• Calidad de la anticoagulación con antagonistas de la vitamina K en España: prevalencia de mal control y factores asociados

  2015cited by this paper
• Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological sub-type.

  2014cited by this paper
• Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological sub-type

  2014cited by this paper
• Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

  2014cited by this paper
• Edoxaban Transport via P-Glycoprotein Is a Key Factor for the Drug’s Disposition

  2014cited by this paper
• Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

  2014cited by this paper
• Secondary stroke prevention in atrial fibrillation: a challenge in the clinical practice

  2014cited by this paper
• Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs).

  2014cited by this paper
• Abstract 12680: Efficacy and Safety of Edoxaban Compared With Warfarin in Patients With Atrial Fibrillation and Heart Failure: Insights From Engage-AF TIMI 48

  2014cited by this paper
• Antithrombotic Therapy After Acute Ischemic Stroke in Patients With Atrial Fibrillation

  2014cited by this paper
• [Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack].

  2014cited by this paper
• Edoxaban

  2014cited by this paper
• Edoxaban: a focused review of its clinical pharmacology.

  2014cited by this paper
• Use of PER977 to reverse the anticoagulant effect of edoxaban.

  2014cited by this paper
• Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

  2014cited by this paper
• Abstract 19119: Concomitant Use of Antiplatelet Therapy with Edoxaban or Warfarin in Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

  2014cited by this paper
• Manejo actual del tratamiento antitrombótico en pacientes con fibrilación auricular no valvular y antecedentes de ictus o ataque isquémico transitorio

  2014cited by this paper
• Abstract 16612: Efficacy and Safety of Edoxaban for the Management of Elderly Patients With Atrial Fibrillation: Engage AF-TIMI 48

  2014cited by this paper
• Secondary prevention after ischemic stroke or transient ischemic attack.

  2014cited by this paper
• Hemorragias en pacientes anticoagulados: utilidad real de los antídotos y modo de actuación con los nuevos anticoagulantes orales

  2013cited by this paper
• Edoxaban versus warfarin in patients with atrial fibrillation.

  2013cited by this paper
• New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons

  2013cited by this paper
• Impact of Atrial Fibrillation on Stroke‐Related Healthcare Costs

  2013cited by this paper
• Patients with atrial fibrillation in a primary care setting: Val-FAAP study.

  2012cited by this paper
• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

  2012cited by this paper
• Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Impact of Daily Dosing Frequency on Adherence to Chronic Medications Among Nonvalvular Atrial Fibrillation Patients

  2012cited by this paper
• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

  2012cited by this paper
• Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Patients with atrial fibrillation in a primary care setting: Val-FAAP study.

  2012cited by this paper
• Emergency Management of Bleeding Associated With Old and New Oral Anticoagulants

  2012cited by this paper
• Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

  2011cited by this paper
• Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

  2010cited by this paper
• Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

  2010cited by this paper
• Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

  2010cited by this paper
• Independent predictors of stroke in patients with atrial fibrillation

  2007cited by this paper
• Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry.

  2004cited by this paper
• Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

  1991cited by this paper
• Vascular Health and Risk Management Dovepress Secondary Stroke Prevention: Challenges and Solutions

  year unknowncited by this paper

• Frequency, Severity, Risk Factors, and Outcome of Hemorrhagic Transformation in Anterior and Posterior Stroke

  2024cites this paper
• Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke

  2020cites this paper
• Edoxaban for the prevention of stroke in patients with atrial fibrillation

  2019cites this paper
• State of play and future direction with NOACs: An expert consensus.

  2018cites this paper
• University of Birmingham State of play and future direction with NOACs:

  2018cites this paper